Biogen has pleased their shareholders in the week after they presented more data on their drug related to late-stage Alzheimer’s. The drug is named Aducanumab.
On Thursday, the shares of the firm engaged in biotech ended up closing higher by 3.41% as the analysts had pointed to there being no further negatives with the results that had come out in the month of October. This may increase the chances that this drug will be approved by the FDA.
The company is still facing a huge battle when it comes to the federal regulator though.
The data which had been produced recently during the Clinical Trials on the conference held in San Diego, as per analysts were somewhat fixed. One of the two trials for Biogen had showed that the drug was meeting the goals of reducing the decline in those who were patients of the disease while the other trials were not showing such results.
FDA may in order to alleviate the concerns of these results ask the company to do one more trial before they consider the approval instead of doing it post market, according to the analysts.
The FDA is going to face a lot of pressure from the advocacy groups, families and patients who live with this disease for the approval of the drugs when Biogen is going to submit this to the regulators which is supposedly going to be in the early months of 2020.
Data says that there are close to 5.8 million people in the United States who are living their lives with disease and there are no drugs which have been approved by FDA which can help reducing the decline that occurs due to the disease.
William holds Master of Business Administration in Finance Degree and leads the team of 7 writers at Packaging Industry Reports. He has deep knowledge of share market and has a long record of being a famous trading consultant in the Business industry from last 10 years. Although William has no family background of business, he demonstrated a keen interest in the business activities from his school days. While he can write news on any topic related to the Business field, he is more focused on the topics that show the impact of advanced technologies in this field. He always keeps himself updated with the latest computer skills.